company background image
LJPC

La Jolla Pharmaceutical NasdaqCM:LJPC Stock Report

Last Price

US$6.22

Market Cap

US$155.1m

7D

0.5%

1Y

59.1%

Updated

22 Aug, 2022

Data

Company Financials +
LJPC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance3/6
Financial Health0/6
Dividends0/6

LJPC Stock Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.

La Jolla Pharmaceutical Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for La Jolla Pharmaceutical
Historical stock prices
Current Share PriceUS$6.22
52 Week HighUS$6.24
52 Week LowUS$3.07
Beta2.41
1 Month Change0.49%
3 Month Change65.87%
1 Year Change59.08%
3 Year Change-36.92%
5 Year Change-81.03%
Change since IPO-100.00%

Recent News & Updates

Recent updates

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Nov 11
We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Mar 11
La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Jan 16
Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Dec 09
Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Shareholder Returns

LJPCUS BiotechsUS Market
7D0.5%3.2%1.1%
1Y59.1%-6.5%-17.6%

Return vs Industry: LJPC exceeded the US Biotechs industry which returned -27.7% over the past year.

Return vs Market: LJPC exceeded the US Market which returned -13.5% over the past year.

Price Volatility

Is LJPC's price volatile compared to industry and market?
LJPC volatility
LJPC Average Weekly Movement23.8%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: LJPC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: LJPC's weekly volatility has increased from 14% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198961Larry Edwardshttps://www.lajollapharmaceutical.com

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States.

La Jolla Pharmaceutical Company Fundamentals Summary

How do La Jolla Pharmaceutical's earnings and revenue compare to its market cap?
LJPC fundamental statistics
Market CapUS$155.11m
Earnings (TTM)US$3.97m
Revenue (TTM)US$46.49m

39.1x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LJPC income statement (TTM)
RevenueUS$46.49m
Cost of RevenueUS$8.87m
Gross ProfitUS$37.62m
Other ExpensesUS$33.65m
EarningsUS$3.97m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.16
Gross Margin80.92%
Net Profit Margin8.54%
Debt/Equity Ratio-179.3%

How did LJPC perform over the long term?

See historical performance and comparison